Search Results

Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, announced its partner, DEKA Research & Development Corp., has received 510 clearance from the U.S. Food and Drug Administration for the innovative twiist™ Automated Insulin Delivery system powered by Tidepool.

Sequel, a startup, dedicated to engineering better health and wellness experiences for women, today announced that its breakthrough spiral tampon has received approval from the United States Food and Drug Administration (FDA) as a medical device.

Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced that Willem de Haan, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers’ Alzheimer Center, is presenting complete EEG findings from the Phase 2 SEQUEL study at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator.

Cognition Therapeutics, Inc. today announced topline results from its Phase 2 double-blind, single-crossover SEQUEL study (NCT04735536) of CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease.

Cognition Therapeutics, Inc. announced that it will host a conference call and webcast on June 28, 2023, at 8:00am ET to discuss topline results from its Phase 2 SEQUEL Study for mild-to-moderate Alzheimer’s disease.

Cognition Therapeutics, Inc. (Nasdaq: CGTX) today announced that enrollment has completed in the randomized, double-blind Phase 2 SEQUEL study (COG0202, NCT04735536) of CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease.

Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to support completion of the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer’s disease.